Table 1 |
|||||||
|
Clinical Laboratory findings |
|||||||
|
Haematology and biochemistry tests |
Reference range |
Screening |
Admission |
Adm +1 |
Adm +2 |
Adm +3 |
Adm +4 = Discharge |
|
|
|||||||
|
Haemoglobin (mmol/l) |
7.3 - 9.7 |
7.1 |
6.9 |
7.1 |
6.9 |
||
|
|
|||||||
|
Leukocytes (*109/l) |
3.5 - 11.0 |
6.6 |
7.9 |
3.9 |
5.4 |
||
|
|
|||||||
|
Platelets (*109/l) |
120 - 350 |
259 |
160 |
254 |
302 |
||
|
|
|||||||
|
Glucose (mmol/l) |
4.0 - 5.5 (fasting) |
4.6 |
4.9 |
||||
|
|
|||||||
|
Sodium (mmol/l) |
137 - 144 |
142 |
140 |
137 |
|||
|
|
|||||||
|
Potassium (mmol/l) |
3.4 - 4.6 |
4.1 |
3.9 |
3.9 |
|||
|
|
|||||||
|
Creatinin (umol/l) |
45 - 90 |
61 |
55 |
60 |
|||
|
|
|||||||
|
Urea nitrogen (mmol/l) |
3.0 - 7.0 |
4.9 |
3.2 |
||||
|
|
|||||||
|
Bilirubin (umol/l) |
≤ 17 |
<10 |
<10 |
||||
|
|
|||||||
|
Alkaline phosphatase (U/l) |
≤ 120 |
55 |
74 |
66 |
69 |
69 |
|
|
|
|||||||
|
Aspartate aminotransferase (U/l) |
≤ 40 |
16 |
132 |
104 |
111 |
89 |
83 |
|
|
|||||||
|
Alanine aminotransferase (U/l) |
≤ 45 |
15 |
137 |
134 |
171 |
166 |
164 |
|
|
|||||||
|
Lactate dehydrogenase (U/l) |
≤ 450 |
313 |
540 |
534 |
562 |
384 |
|
|
|
|||||||
|
gamma GT (U/l) |
≤ 35 |
13 |
29 |
39 |
36 |
35 |
|
|
|
|||||||
|
Creatinin Kinase (U/l) |
≤ 170 |
296 |
105 |
28 |
|||
|
|
|||||||
|
Troponin I (ug/l) |
≤ 0.20 |
10.40 |
2.75 |
0.20 |
|||
|
|
|||||||
|
CRP (mg/l) |
≤ 10 |
26 |
|||||
|
|
|||||||
|
Cholesterol (mmol/l) |
4.7 - 6.5 |
4.0 |
|||||
|
|
|||||||
|
Triglycerides (mmol/l) |
0.8 - 2.0 |
1.5 |
|||||
|
|
|||||||
|
HDL cholesterol (mmol/l) |
1.10 - 1.70 |
1.20 |
|||||
|
|
|||||||
|
LDL cholesterol (mmol/l) |
≤ 3.5 |
2.12 |
|||||
|
|
|||||||
|
|
|||||||
|
Coagulation assays |
|||||||
|
|
|||||||
|
INR |
0.9-1.1 |
1.0 |
1.0 |
||||
|
|
|||||||
|
Fibrinogen (mg/l) |
2000-4000 |
4320 |
|||||
|
|
|||||||
|
Factor VIII activity (%) |
60-150 |
130% |
|||||
|
|
|||||||
|
Protein C activity (%) |
70-150 |
>100% |
|||||
|
|
|||||||
|
Free protein S antigen (%) |
55-115 |
92% |
|||||
|
|
|||||||
|
Homocystein (μmol/l) |
< 13.4 |
9.3 |
|||||
|
|
|||||||
|
Antithrombin III (%) |
85-120 |
98% |
|||||
|
|
|||||||
|
Factor II mutation |
negative |
negative |
|||||
|
|
|||||||
|
Factor V (Leiden) mutation |
negative |
negative |
|||||
|
|
|||||||
|
von Willebrand Factor (%) |
50-150 |
166% |
|||||
|
|
|||||||
|
ADAMTS13 activity (%) |
60-140 |
90% |
|||||
|
|
|||||||
|
|
|||||||
|
Additional tests |
|||||||
|
|
|||||||
|
Convalescent microbiological tests |
adenovirus, RS-virus, influenza virus, mycoplasma pneumonia, Chlamydia, Q-fever, para-influenza, enterovirus |
Negative |
|||||
|
Auto-immune antibodies |
ANCA, anticardiolipin antibodies, β2 glycoprotein, lupus anticoagulans, anti-heart (rat) antibodies |
Negative |
|||||
|
Toxicology test |
tetrahydrocannabinol, amphetamine-derivatives, cocaine, diazepam, methadone, tramadol, opiates |
Negative |
|||||
|
|
|||||||
|
Inflammatory parameters |
Interleukin 6, Interleukin 8 |
< detection limit |
|||||
|
|
|||||||
|
|
|||||||
|
Time after last dose |
7 h15 |
103 h45 |
|||||
|
Artemether |
< detection limit |
< detection limit |
|||||
|
Dihydroartemisinin |
26.5 ng/ml |
< detection limit |
|||||
|
Lumefantrine |
4308 ng/ml and |
443 ng/ml |
|||||
|
Desbutyl-lumefantrine |
40 ng/ml |
18 ng/ml |
|||||
|
|
|||||||
|
Nieman et al. Malaria Journal 2009 8:277 doi:10.1186/1475-2875-8-277 |
|||||||